{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Proportion of subjects with a DOR ≥ 16 weeks per RECIST 1.1","groups":[{"description":"Participants with advanced or metastatic biliary tract cancer with HER2 amplification by in situ hybridization (ISH) and HER2 overexpression by immunohistochemistry (IHC) which includes IHC 2+ or 3+","id":"OG000","title":"Cohort I"},{"description":"Participants with advanced or metastatic biliary tract cancer with HER2 amplification by ISH and HER2 IHC 0 or 1+.","id":"OG001","title":"Cohort II"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Only participants with a response (a confirmed Complete Response (CR) or confirmed Partial Response (PR)) as per investigator assessment, were evaluated for this outcome.","reportingStatus":"POSTED","timeFrame":"24 weeks, up to 45 months","title":"DOR ≥ 16 Weeks by Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Participants"}